6.1 Investigational Product Labeling and Storage

Investigational Product (IP) Labeling Requirements

The labeling of an investigational product (IP) is a fundamental aspect of clinical trial safety and compliance. Unlike commercially available medications, an IP is not yet proven safe and effective for the indication under study. Therefore, regulatory bodies like the FDA and EMA impose strict rules on how these products must be labeled to prevent misuse and ensure that both the research staff and the subjects are fully aware of the product's investigational nature.

Mandatory Label Elements

In the United States, under 21 CFR Part 312, the immediate package of an investigational new drug intended for human use must bear a label with the statement: "Caution: New Drug - Limited by Federal (or United States) law to investigational use."

Beyond this mandatory statement, Good Clinical Practice (GCP) guidelines dictate that IP labels generally include:

• The sponsor's name, address, and telephone number.
• The pharmaceutical formulation, route of administration, and quantity of dosage units.
• The batch or lot number.
• The clinical trial reference code or protocol number.
• The subject identification number and/or treatment number, where applicable.
• Directions for use, or a reference to a patient instruction sheet.
• Storage conditions.
• The expiration or retest date (though this is sometimes managed via interactive response technology [IRT] systems to allow for expiry updates without relabeling).
• The phrase "Keep out of reach of children."

Blinding and Randomization in Labeling

In blinded trials, the labeling must ensure that the identity of the IP (active vs. placebo) remains concealed. This is typically achieved using identical packaging and labeling for all treatment arms, differentiated only by a unique kit or treatment number. The label must not contain any information that could inadvertently break the blind.

Real-World Example: In a Phase III double-blind trial for a novel oncology drug, both the active drug and the placebo are formulated as visually identical clear liquids in matching vials. The labels on both vials are identical except for the kit number (e.g., Kit #10452 vs. Kit #10453). When the coordinator registers a subject in the IRT system, the system assigns a specific kit number. The coordinator retrieves that exact kit, ensuring the blind is maintained.

---

IP Storage Conditions and Facility Requirements

The storage of investigational products is critical. An IP that degrades due to improper storage can jeopardize the safety of the subject and the validity of the trial data. The Principal Investigator (PI) is ultimately responsible for IP accountability at the site, which includes ensuring proper storage.

Essential Storage Facility Features

Clinical sites must designate a specific, secure area for IP storage. The key requirements include:

Temperature Monitoring and Logging

Continuous temperature monitoring is the gold standard for IP storage. Depending on the product, storage may require:

• Ambient/Room Temperature: Typically 15°C to 25°C (59°F to 77°F).
• Refrigerated: Typically 2°C to 8°C (35.6°F to 46.4°F).
• Frozen: Often -20°C (-4°F) or ultra-low -70°C to -80°C (-94°F to -112°F).

Sites must use calibrated continuous temperature monitoring devices (data loggers) that record the temperature at regular intervals. A manual min/max thermometer checked daily is often used as a backup, but continuous logs are heavily preferred by sponsors and auditors.

Best Practice: Calibrate temperature monitoring equipment annually or according to the manufacturer's recommendations, and keep the calibration certificates in the site's regulatory binder.

---

Managing Temperature Excursions

A temperature excursion occurs when the IP is exposed to conditions outside the protocol-specified range. Handling these events correctly is a frequent focus during site monitoring visits and FDA audits.

The Excursion Workflow

1. Identify and Quarantine: Immediately upon discovering an excursion (e.g., an alarm sounds, or a data logger shows the fridge hit 9°C for two hours), the affected IP must be physically separated and clearly marked as "QUARANTINED - DO NOT USE."
2. Document: Download the temperature data and document the highest/lowest temperature reached and the total duration of the excursion.
3. Report: Notify the sponsor or Contract Research Organization (CRO) immediately, usually by submitting a formal Temperature Excursion Form.
4. Wait for Disposition: The sponsor will review the stability data for the product and determine if it is still safe to use.
5. Action: The site must wait for written authorization from the sponsor before either returning the IP to active stock or destroying/returning it.

Never dispense an IP that has experienced an excursion until explicit, written approval from the sponsor is received.

---

Unblinding Procedures

While maintaining the blind is crucial, there are rare medical emergencies where the treating physician must know what the subject received to provide proper care (e.g., an unexpected severe adverse event that requires specific antidotes).

The protocol will outline the unblinding procedure. Historically, this involved opening a sealed, tamper-evident envelope. Today, it is almost exclusively managed through the IRT system. If an investigator needs to unblind, they log into the system, select the subject, and request unblinding. The system immediately reveals the treatment assignment and generates audit trails notifying the sponsor.

Sites must ensure that all relevant staff are trained on the emergency unblinding procedure and have the necessary access credentials at all times.